7B0B
 
 | | Fab HbnC3t1p1_C6 bound to SARS-CoV-2 RBD | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Fab heavy chain, IGK@ protein, ... | | Authors: | Borenstein-Katz, A, Diskin, R. | | Deposit date: | 2020-11-19 | | Release date: | 2021-12-01 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (2.98 Å) | | Cite: | Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants.
Immunity, 56, 2023
|
|
8BF0
 | |
4ISV
 | | Crystal structure of the Fab FRAGMENT OF 1C2, A MONOCLONAL ANTIBODY SPECIFIC FOR POLY-GLUTAMINE | | Descriptor: | 1C2 FAB HEAVY CHAIN, 1C2 FAB LIGHT CHAIN | | Authors: | Klein, F.A.C, Zeder-Lutz, G, Cousido-Siah, A, Mitschler, A, Katz, A, Eberling, P, Mandel, J.L, Podjarny, A, Trottier, Y. | | Deposit date: | 2013-01-17 | | Release date: | 2013-07-03 | | Last modified: | 2017-11-15 | | Method: | X-RAY DIFFRACTION (1.497 Å) | | Cite: | Linear and extended: a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10.
Hum.Mol.Genet., 22, 2013
|
|
4JJ5
 | | CRYSTAL STRUCTURE OF THE Fab FRAGMENT OF 1C2, A MONOCLONAL ANTIBODY SPECIFIC for POLY-GLUTAMINE | | Descriptor: | 1C2 FAB HEAVY CHAIN, 1C2 FAB LIGHT CHAIN | | Authors: | Klein, F.A.C, Zeder-Lutz, G, Cousido-Siah, A, Mitschler, A, Katz, A, Eberling, P, Mandel, J.L, Podjarny, A, Trottier, Y. | | Deposit date: | 2013-03-07 | | Release date: | 2013-07-03 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (2.445 Å) | | Cite: | Linear and extended: a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10.
Hum.Mol.Genet., 22, 2013
|
|
6XTG
 | | Ab 1116NS19.9 bound to CA19-9 | | Descriptor: | Heavy chain, Light chain, N-acetyl-alpha-neuraminic acid-(2-3)-beta-D-galactopyranose-(1-3)-[alpha-L-fucopyranose-(1-4)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | Authors: | Diskin, R, Borenstein-Katz, A. | | Deposit date: | 2020-01-16 | | Release date: | 2021-01-27 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.55 Å) | | Cite: | Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies.
J.Mol.Biol., 433, 2021
|
|
6XUN
 | | Ab 5b1 bound to CA19-9 | | Descriptor: | GLYCEROL, Heavy chain, Light chain, ... | | Authors: | Diskin, R, Borenstein-Katz, A. | | Deposit date: | 2020-01-20 | | Release date: | 2021-02-03 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.41 Å) | | Cite: | Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies.
J.Mol.Biol., 433, 2021
|
|
6XUK
 | | AbLIFT design 15 of Ab 1116NS19.9 | | Descriptor: | GLYCEROL, Heavy chain, Light chain, ... | | Authors: | Diskin, R, Borenstein-Katz, A. | | Deposit date: | 2020-01-20 | | Release date: | 2021-02-03 | | Last modified: | 2024-02-07 | | Method: | X-RAY DIFFRACTION (1.42 Å) | | Cite: | Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies.
J.Mol.Biol., 433, 2021
|
|
6XUD
 | | Apo Ab 1116NS19.9 | | Descriptor: | Heavy chain, Light chain | | Authors: | Diskin, R, Borenstein-Katz, A. | | Deposit date: | 2020-01-19 | | Release date: | 2021-01-27 | | Last modified: | 2021-09-29 | | Method: | X-RAY DIFFRACTION (1.51 Å) | | Cite: | Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies.
J.Mol.Biol., 433, 2021
|
|
6XUL
 | | Apo Ab 5b1 | | Descriptor: | Heavy chain, Light chain | | Authors: | Diskin, R, Borenstein-Katz, A. | | Deposit date: | 2020-01-20 | | Release date: | 2021-02-03 | | Last modified: | 2023-03-08 | | Method: | X-RAY DIFFRACTION (2.41 Å) | | Cite: | Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies.
J.Mol.Biol., 433, 2021
|
|
6GC2
 | | AbLIFT: Antibody stability and affinity optimization by computational design of the variable light-heavy chain interface | | Descriptor: | Heavy chain, Light Chain | | Authors: | Warszawski, S, Katz, A, Khmelnitsky, L, Ben Nissan, G, Javitt, G, Dym, O, Unger, T, Knop, O, Diskin, R, Albeck, S, Fass, D, Sharon, M, Fleishman, S.J. | | Deposit date: | 2018-04-17 | | Release date: | 2019-05-01 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (2.55 Å) | | Cite: | Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces.
Plos Comput.Biol., 15, 2019
|
|
4PDN
 | | Crystal structure of E. coli YfcM | | Descriptor: | MAGNESIUM ION, Uncharacterized protein | | Authors: | Kobayashi, K, Ishii, R, Ishitani, R, Nureki, O. | | Deposit date: | 2014-04-19 | | Release date: | 2015-03-04 | | Last modified: | 2024-03-20 | | Method: | X-RAY DIFFRACTION (1.448 Å) | | Cite: | The non-canonical hydroxylase structure of YfcM reveals a metal ion-coordination motif required for EF-P hydroxylation.
Nucleic Acids Res., 42, 2014
|
|
3WTR
 | | Crystal structure of E. coli YfcM bound to Co(II) | | Descriptor: | COBALT (II) ION, Uncharacterized protein | | Authors: | Kobayashi, K, Ishii, R, Ishitani, R, Nureki, O. | | Deposit date: | 2014-04-19 | | Release date: | 2015-04-01 | | Last modified: | 2023-11-08 | | Method: | X-RAY DIFFRACTION (1.96 Å) | | Cite: | The non-canonical hydroxylase structure of YfcM reveals a metal ion-coordination motif required for EF-P hydroxylation
Nucleic Acids Res., 42, 2014
|
|
6OLA
 | | Structure of the PCV2d virus-like particle | | Descriptor: | Capsid protein, DNA (5'-D(P*CP*CP*GP*G)-3') | | Authors: | Khayat, R, Wen, K, Alimova, A, Galarza, J, Gottlieb, P. | | Deposit date: | 2019-04-16 | | Release date: | 2019-09-25 | | Last modified: | 2024-03-20 | | Method: | ELECTRON MICROSCOPY (3.3 Å) | | Cite: | Structural characterization of the PCV2d virus-like particle at 3.3 angstrom resolution reveals differences to PCV2a and PCV2b capsids, a tetranucleotide, and an N-terminus near the icosahedral 3-fold axes.
Virology, 537, 2019
|
|
6B5X
 | | Beta-Lactamase, unmixed shards crystal form | | Descriptor: | Beta-lactamase, PHOSPHATE ION | | Authors: | Pandey, S. | | Deposit date: | 2017-09-29 | | Release date: | 2018-06-27 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (2.45 Å) | | Cite: | Enzyme intermediates captured "on the fly" by mix-and-inject serial crystallography.
BMC Biol., 16, 2018
|
|
6B6F
 | |
6B69
 | | Beta-Lactamase, 500ms timepoint, mixed, shards crystal form | | Descriptor: | (2R)-2-[(1S)-1-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2-hydroxyethyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid, (2R)-2-[(S)-{[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}(carboxy)methyl]-5-(hydroxymethyl)-3,6-dihydro-2H-1,3-thiazine-4-carboxylic acid, Beta-lactamase, ... | | Authors: | Pandey, S, Schmidt, M. | | Deposit date: | 2017-10-01 | | Release date: | 2018-06-27 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (2.2 Å) | | Cite: | Enzyme intermediates captured "on the fly" by mix-and-inject serial crystallography.
BMC Biol., 16, 2018
|
|
6B6D
 | | Beta-Lactamase, mixed with Ceftriaxone, needles crystal form, 100ms | | Descriptor: | (2R)-2-[(1S)-1-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2-hydroxyethyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid, Beta-lactamase, Ceftriaxone | | Authors: | Pandey, S, Schmidt, M. | | Deposit date: | 2017-10-01 | | Release date: | 2018-06-27 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Enzyme intermediates captured "on the fly" by mix-and-inject serial crystallography.
BMC Biol., 16, 2018
|
|
6B5Y
 | | Beta-lactamase, mixed with Ceftriaxone, 30ms time point, Shards crystal form | | Descriptor: | Beta-lactamase, Ceftriaxone, PHOSPHATE ION | | Authors: | Pandey, S, Schmidt, M. | | Deposit date: | 2017-09-29 | | Release date: | 2018-06-27 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (2.75 Å) | | Cite: | Enzyme intermediates captured "on the fly" by mix-and-inject serial crystallography.
BMC Biol., 16, 2018
|
|
6B6B
 | |
6B6A
 | | Beta-Lactamase, 2secs timepoint, mixed, shards crystal form | | Descriptor: | (2R)-2-[(1S)-1-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2-hydroxyethyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid, Beta-lactamase, Ceftriaxone, ... | | Authors: | Pandey, S, Schmidt, M. | | Deposit date: | 2017-10-01 | | Release date: | 2018-06-27 | | Last modified: | 2020-01-15 | | Method: | X-RAY DIFFRACTION (2.298 Å) | | Cite: | Enzyme intermediates captured "on the fly" by mix-and-inject serial crystallography.
BMC Biol., 16, 2018
|
|
6B6C
 | |
6B6E
 | | Beta-Lactamase, mixed with Ceftriaxone, needles crystal form, 500ms | | Descriptor: | (2R)-2-[(1S)-1-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2-hydroxyethyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid, Beta-lactamase, Ceftriaxone | | Authors: | Pandey, S, Schmidt, M. | | Deposit date: | 2017-10-01 | | Release date: | 2018-06-27 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (1.901 Å) | | Cite: | Enzyme intermediates captured "on the fly" by mix-and-inject serial crystallography.
BMC Biol., 16, 2018
|
|
6B68
 | | Beta-Lactamase, 100ms timepoint, mixed, shards crystal form | | Descriptor: | (2R)-2-[(1S)-1-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-2-hydroxyethyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid, Beta-lactamase, Ceftriaxone, ... | | Authors: | Pandey, S, Schmidt, M. | | Deposit date: | 2017-10-01 | | Release date: | 2018-06-27 | | Last modified: | 2024-03-13 | | Method: | X-RAY DIFFRACTION (2.15 Å) | | Cite: | Enzyme intermediates captured "on the fly" by mix-and-inject serial crystallography.
BMC Biol., 16, 2018
|
|
6S9J
 | | Crystal structure of TfR1 mimicry in complex with GP1 from MACV | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Pre-glycoprotein polyprotein GP complex, ... | | Authors: | Diskin, R, Cohen-Dvashi, H. | | Deposit date: | 2019-07-15 | | Release date: | 2020-01-15 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.698 Å) | | Cite: | Rational design of universal immunotherapy for TfR1-tropic arenaviruses.
Nat Commun, 11, 2020
|
|
